INTRODUCTION

CASE REPORT
A 60-year-old woman presented to the emergency department with hematochezia. She was admitted to another hospital when this symptom developed two weeks previously. Her medical history included a skull cavernous hemangioma, resected 10 years previously, and a huge hepatic hemangioma detected eight years previously. For the resolution of her epigastric discomfort and pain, surgical resection was considered, but at that time the surgeon recommended liver transplantation because of technical problems related to its large size (it occupied most of the right hepatic lobe). However, her disseminated intravascular coagulopathy profile was within the normal range at that time, and she refused surgery. She then was not seen for five years.
On admission, physical examination showed a distended right upper quadrant with a hard palpable mass, and generalized ecchymosis was observed on the trunk and extremities ( Fig. 1 ). Fresh bloody stool was noted on digital rectal exam.
On laboratory testing, her hemoglobin level was 8.2 g/dL, and platelet count was 32,000/mm (Fig. 2A,   B ), increased over the abdominal computed tomography of eight years prior (Fig. 2C) . Sigmoidoscopy showed diffuse mucosal bleeding, but an active bleeding focus was not found. Despite packed red blood cell concentrate and platelet concentrate, fresh frozen plasma, and cryoprecipitate transfusions, bleeding tendency and coagulation profiles
were not corrected completely (Table 1) . We recommended liver transplantation for removal of the giant hepatic hemangioma. However, the patient and her family refused any surgical management. Therefore, we decided to start medical treatment with steroid therapy and a beta-blocker.
Prednisone at a dose of 3 mg/kg/day (total dose, 125 mg) and 20 mg of propranolol twice a day were administered for 14 days, followed by a tapering dose. The frequency and amount of hematochezia decreased by the fourth day of ste-
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The Korean Journal of Gastroenterology roid therapy. Coagulation time stabilized on the twelfth day without transfusion. Fibrinogen and fibrin split product levels were not normalized completely despite steroid therapy, but the fibrinogen level slightly increased to 60 mg/dL, and the FDP and D-dimer levels decreased to 241.7 g/mL and 35.2 mg/L FEU, respectively, at the19th day without transfusion.
The platelet count improved at the 29th day to 96,000/mm 3 .
We concluded that these laboratory findings were appropriate for partial response and decided to continue steroid therapy. Although partial response was observed, complete correction of laboratory results was not expected due to the residual hepatic lesion in this patient. We considered combination therapy with vincristine, interferon therapy, or radiation therapy as second line treatment due to her slow response, but the patient and her family refused further treatment. As the laboratory findings had stabilized, she was discharged on hospital day 33 on 30 mg/day of oral prednisolone. Three months later, the patient is still alive. She has been admitted to hospital care, and did not attend our hospital, but her local laboratory results showed no aggravation of coagulopathy.
DISCUSSION
KMS is a rare, life-threatening thrombocytopenic coagulopathy associated with a large vascular lesion, with significant morbidity and mortality (up to 30%). 12 This syndrome is characterized by thrombocytopenia, hypo-fibrinogenemia, and elevated fibrin split products. 13 The pathogenesis is trig- KMS with hepatic hemangioma in adults is rare, considering the high prevalence of hepatic hemangiomas. A diagnosis of KMS should be considered for patients with hemangioma who complain of symptoms such as bleeding tendency, and who have a giant hepatic hemangioma (ranging from 7 to 25 cm) or multiple giant hemangiomas found on imaging studies. [7] [8] [9] [10] [11] Therefore, it is important to consider the possibility of KMS in patients with giant hemangiomas and bleeding tendency.
We should check the complete blood cell count and coagulation profiles to exclude KMS in these patients. However, a large study will be needed to confirm these findings.
